New CEOs Need Digit...
Health Care: Drugs
Alkermes PLC (ALKS: NASDAQ)
$28.91 -1.00 | -3.34%
06/19/13 - 04:00 PM ET
Company Income Statement
| Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
| Sales | 575.55M | 389.98M | 186.64M | 178.28M |
| Cost of Sales | 138.57M | 105.05M | 43.53M | 24.41M |
| Gross Operating Profit | 436.98M | 284.93M | 143.11M | 153.87M |
| Selling, General, and Administrative Expenses | 125.76M | 137.63M | 82.85M | 76.51M |
| Research & Development | 140.01M | 141.89M | 97.24M | 95.36M |
| Operating Income before D & A (EBITDA) | 171.21M | 5.40M | -36.98M | -18.01M |
| Depreciation & Amortization | 73.75M | 93.68M | 8.65M | 25.03M |
| Interest Income | 841.00K | 1.52M | 2.73M | 4.67M |
| Other Income - Net | 1.78M | 484.00K | -290.00K | -360.00K |
| Special Income / Charges | -3.35M | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | 84.44M | -86.28M | -43.19M | -38.73M |
| Interest Expense | 48.99M | 28.11M | 3.30M | 5.97M |
| Pre-Tax Income | 35.44M | -114.39M | -46.49M | -44.70M |
| Income Taxes | 10.46M | -714.00K | -951.00K | -5.08M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | 24.98M | -113.68M | -45.54M | -39.63M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | 24.98M | -113.68M | -45.54M | -39.63M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | 24.98M | -113.68M | -45.54M | -39.63M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
40.63M | -113.68M | -45.54M | -39.63M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | 24.98M | -113.68M | -45.54M | -39.63M |
| Basic EPS from Continuing Ops. | 0.19 | -0.99 | -0.48 | -0.42 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | 0.19 | -0.99 | -0.48 | -0.42 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | 0.19 | -0.99 | -0.48 | -0.42 |
| Basic Normalized Net Income/Share | 0.31 | -0.99 | -0.48 | -0.42 |
| EPS fr Continuing Ops. | 0.18 | -0.99 | -0.48 | -0.42 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | 0.18 | -0.99 | -0.48 | -0.42 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | 0.18 | -0.99 | -0.48 | -0.42 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0.29 | -0.99 | -0.48 | -0.42 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ALKS
- Portfolio NameUser Type
- ContributorTechnical Setups for the We...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- UserInvestments
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- Usergterryburns
- Usermitetwo Portfolio 1
Latest ALKS Headlines from TheStreet
- Alkermes PLC Stock Downgraded (ALKS) 06.19.13 | 10:06 am
- Analysts' Actions: ALKS CBI CMA SEAS 05.29.13 | 08:05 am
- ALKS July Options Begin Trading 05.20.13 | 02:05 pm
- Alkermes Stock Hits New 52-Week High (ALKS) 05.20.13 | 10:05 am
- SALT 2013: The 5 Best Ideas of the Year Ahead 05.10.13 | 04:05 pm
- Alkermes Stock Hits New 52-Week High (ALKS) 04.19.13 | 02:04 pm
- Cramer's 6 Stocks in 60 Seconds: LDK ALKS APA BBY UNP HFC (Update 1) 04.18.13 | 05:04 pm
- 3 Stocks Advancing The Health Care Sector 04.17.13 | 01:04 pm
- Three Cheers For Alkermes Running A Depression Study In The US of A 04.17.13 | 10:04 am
- Alkermes Stock Gaps Up On Today's Open (ALKS) 04.17.13 | 10:04 am
Press Releases for ALKS
- Alkermes’ Corporate Presentation To Be Webcast At Three Upcoming Conferences - Business Wire 02.19.13 | 04:02 pm
- Alkermes’ Corporate Presentation To Be Webcast At Two Upcoming Conferences - Business Wire 02.05.13 | 04:02 pm
- Alkermes Plc Reports Third Quarter Fiscal 2013 Financial Results - Business Wire 01.31.13 | 07:01 am
- Alkermes To Host Conference Call To Discuss Financial Results For Third Quarter Of Fiscal 2013 - Business Wire 01.24.13 | 04:01 pm
- Alkermes Announces Notice Of Allowance Of Key U.S. Patent For Aripiprazole Lauroxil, A New Schizophrenia Drug Candidate - Business Wire 01.03.13 | 07:01 am
- Alkermes Expands CNS Pipeline And Announces Positive Results From Phase 1 Study Of ALKS 3831, A Novel Antipsychotic Therapy For The Treatment Of Schizophrenia - Business Wire 01.03.13 | 07:01 am
- Alkermes’ Corporate Presentation To Be Webcast At The 31st Annual J.P. Morgan Healthcare Conference - Business Wire 01.02.13 | 04:01 pm
- Alkermes And Collaborators To Present Data From Three Ongoing Clinical Development Programs At Two Major Medical Meetings - Business Wire 12.03.12 | 07:12 am
- Alkermes’ Corporate Presentation To Be Webcast At Two Upcoming Conferences - Business Wire 11.07.12 | 04:11 pm
- Alkermes Plc Reports Second Quarter Fiscal 2013 Financial Results - Business Wire 11.01.12 | 07:11 am
Partner Headlines for ALKS
- Alkermes Leaps On Study Results, May Offer New Entry - Investor's Business Daily 04.17.13 | 05:04 pm
- Indexes Notch Sharp Declines; New 52-Week Low For Apple - Investor's Business Daily 04.17.13 | 04:04 pm
- Stocks Hold Near Lows, But Alkermes Soars To New High - Investor's Business Daily 04.17.13 | 03:04 pm
- Biotech Alkermes Poised To Swell On Pipeline Wins - Investor's Business Daily 04.16.13 | 05:04 pm
- Pockets of Strength In Top Groups, Few Leaders Basing - Investor's Business Daily 04.15.13 | 06:04 pm
- Alkermes Aims At Bipolar, Addiction Markets To Grow - Investor's Business Daily 04.15.13 | 04:04 pm
- Biotech Watch-List: Medicine Co., Alkermes, Celgene - Investor's Business Daily 03.11.13 | 05:03 pm
- Foreign Stocks Also Fall In A Correction - Investor's Business Daily 02.26.13 | 05:02 pm
- Alkermes Finding Support At 10-Week Average - Investor's Business Daily 02.21.13 | 05:02 pm
- Stocks Hold Near Session Lows; Generac Stumbles - Investor's Business Daily 02.21.13 | 03:02 pm
